Skip to content

Assessing the use of a smartphone application to support adherence to inhaled corticosteroids, i.e. preventer/controller inhalers, in young adults (18-30 years) with asthma

A smartphone application to support adherence to inhaled corticosteroids in young adults (18-30 years) with asthma: a usability, acceptability, and feasibility study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN11295269
Enrollment
74
Registered
2021-01-18
Start date
2020-09-21
Completion date
Unknown
Last updated
2021-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma Respiratory Asthma

Interventions

‘AsthmaMD’ was developed by Dr Sam Pejham, a physician and researcher from the University of California San Francisco, Medical School Clinical Faculty. ‘AsthmaMD’ allows users to log their peak flow m
this is at the users’ discretion. No other physical or informational materials are provided to participants as part of the intervention. The intervention duration is 2 weeks based on recent feasibilit

Sponsors

National University of Ireland
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age between 18-30 years on date of recruitment 2. Diagnosis of asthma 3. Current prescription for any form of ICS 4. Own a smartphone

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

MeasureTime frame
1. Usability of the app is measured using the System Usability Scale (SUS) at 2-week follow-up 2. Acceptability of the app measured using questions modified from previous feasibility studies of mHealth interventions (Huang et al., 2019; Zhang et al., 2019) at 2-week follow-up 3. Feasibility of the app measured using frequently used questions modified from previous feasibility studies of mHealth interventions (Edbrooke-Childs et al., 2019; Escobar-Viera et al., 2020; Hightow-Weidman et al., 2018; Huang et al., 2019; Zhang et al., 2019) at 2-week follow-up

Secondary

MeasureTime frame
1. Source of recruitment measured by asking participants how they heard about the study at baseline 2. Attrition measured using the number of participants who consent to participate and who remain in the study until the end of follow-up at 2 weeks 3. Adherence to ICS measured using the Medication Adherence Report Scale for Asthma (MARS-A) at baseline and 2-week follow-up 4. Asthma control measured using the Asthma Control Test (ACT) at baseline and 2-week follow-up

Countries

Ireland

Contacts

Public ContactJane Murphy
j.murphy51@nuigalway.ie+353 (0)876904980

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 14, 2026